Free tool
Drug Search
Every brand-name drug and biologic application (NDA or BLA) in Drugs@FDA: 5,899 in all. Generic (ANDA) applications are not listed; their reference drug is.
Last checked: Nov 20, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
6 matches for "Biocon Biologics INC"
Brand names that start with your search come first, then marketed and novel drugs.
| Drug | Sponsor | Application | First approved | Programs |
|---|---|---|---|---|
| Kirsty Insulin Aspart-Xjhz | Biocon Biologics INC | BLA761188 | Jul 15, 2025 | |
| Aukelso Denosumab-Kyqq | Biocon Biologics INC | BLA761436 | Sep 16, 2025 | |
| Jobevne Bevacizumab-Nwgd | Biocon Biologics INC | BLA761175 | Apr 9, 2025 | |
| Pebrilzo Pertuzumab | Biocon Biologics INC | BLA761501 | Nov 12, 2026 | |
| Yesafili Aflibercept-Jbvf | Biocon Biologics INC | BLA761274 | May 20, 2024 | |
| Yesintek Ustekinumab-Kfce | Biocon Biologics INC | BLA761406 | Nov 29, 2024 |
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.